Hancheng Cai, Ph.D.

Departamentos

Location

  1. Jacksonville, Florida

Idiomas

English

Hancheng Cai, PhD, is a radiochemist and molecular imaging scientist. My clinical work focus on FDA cGMP PET drug production facility implementation and operation. Briefly, Dr. Cai oversees all the clinical production of PET tracers at Mayo Clinic Florida, leads a team to produce FDA-approved PET drugs for daily clinical use, and investigational tracers (F-18/C-11 labeled compounds as INDs) for PET imaging of cancer cardiovascular disease, and neurological disorders in human.

Dr. Cai's research aims to developing novel radiopharmaceuticals for the imaging and therapy of cancer, neurological disorders, and cardiovascular diseases from preclinical discovery to clinical investigation. Specifically, his research work focus on development novel radiopharmaceuticals for PET imaging of cancer biology/metabolism, immunotherapy, inflammation, and neurological disorders.

  1. 2010
    Postdoctoral Research Associate - Department of RadiologyUniversity of Southern California
  2. 2007
    PhD - Radiopharmaceuticals ScienceGraduate School of Chinese Academy of Sciences

Awards and honors

  1. 2015
    New Investigator Award in Cancer ResearchUniversity of Texas Southwestern Medical Center
  2. 2010
    Radiopharmaceutical Sciences Council Young Investigator AwardSociety of Nuclear Medicine
  3. 2010
    57th SNM Travel AwardSociety of Nuclear Medicine
  4. 2009
    Travel Award18th International Symposium on Radiopharmaceutical Sciences
  5. 2007
    USC Biomedical Imaging Science Initiative Post doctorate FellowshipUniversity of Southern California

Professional memberships

  1. 2022 - present
    Commiittee MemberRadioactive Drug Research Committee, Mayo Clinic Rochester Committees
  2. 2021
    Abstract ReviewerWorld Molecular Imaging Society
  3. 2021 - present
    Commiittee MemberSociety of Nuclear Medicine and Molecular Imaging Committee on Radiopharmaceuticals (COR)
  4. 2020 - present
    MemberWorld Molecular Imaging Society (merger of AMI and SMI)
  5. 2020 - 2021
    Ad Hoc Grant ReviewerNIH Imaging Probes and Contrast Agents [IPCA] study section
  6. 2020 - present
    Abstract ReviewerSociety of Nuclear Medicine and Molecular Imaging
  7. 2020 - present
    MemberWorld Molecular Imaging Society
  8. 2018 - present
    SecretaryMayo Clinic Florida PET Radiochemistry Facility Steering Committee
  9. 2017 - present
    Committee MemberRadiology Research Committee
  10. 2017 - present
    MemberMayo Enterprise Radiology Nuclear Medicine Subspecialty Team and Operations Group
  11. 2017 - present
    MemberMayo Pharmaceutical Formulary Committee Radiopharmaceutical task force
  12. 2014 - 2017
    MemberMember, Radioactive Drug Research Committee of UTSW
  13. 2014 - present
    MemberAmerican Chemical Society
  14. 2014 - present
    MemberAmerican Chemical Society
  15. 2011 - present
    Grant ReviewerNSF Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Program
  16. 2009 - present
    MemberSociety of Radiopharmaceutical Sciences
  17. 2009 - present
    MemberSociety of Radiopharmaceutical Sciences
  18. 2008 - present
    MemberSociety of Nuclear Medicine and Molecular Imaging
  19. 2008 - present
    MemberSociety of Nuclear Medicine and Molecular Imaging

Publications